(Q40762599)

23 September 2017

title

Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma (English)

1 reference

adaptive radiation therapy

23 September 2017

main subject

0 references

1 reference

1 reference

Smith MR

1

1 reference

23 September 2017

Peters WA 3rd

series ordinal

2

1 reference

23 September 2017

Drescher CW

series ordinal

3

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 June 1994

1 reference

American Journal of Obstetrics and Gynecology

23 September 2017

published in

1 reference

23 September 2017

volume

170

1 reference

23 September 2017

issue

6

1 reference

23 September 2017

page(s)

1677-81; discussion 1681-2

1 reference

Features associated with survival and disease-free survival in early endometrial cancer

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Postoperative external pelvic irradiation in carcinoma of the corpus stage I: a controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Stage III carcinoma of the endometrium: a review of 41 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Stage III adenocarcinoma of the endometrium: two prognostic groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

Stage II carcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970340-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9378(94)70340-X

1 reference

23 September 2017

1 reference